MiNK Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for INKT, updated each market day.
INKT AI Sentiment
AI sees no strong directional signal for MiNK Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Sector
Exchange
Market Cap
$56,958,391
Cap Tier
Employees
15
Headquarters
NEW YORK, NY
Listed Since
Oct. 15, 2021
Website
INKT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
INKT Volatility
MiNK Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
